By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NovaRx Corporation 

6828 Nancy Ridge Drive, Suite 100

San Diego  California  92121  U.S.A.
Phone: 858-552-8600 Fax: 858-638-0882


SEARCH JOBS








Company News
NovaRx Corporation Announces Results of Lucanix® Phase III Therapeutic Vaccine Trial for Maintenance Therapy in Non-small Cell Lung Cancer to be Presented at ESMO. 9/26/2013 10:08:46 AM
NovaRx Corporation Announces Results of Lucanix® Phase III Therapeutic Vaccine Trial for Post-frontline Maintenance Therapy in Non-small Cell Lung Cancer to be Presented at ESMO 9/25/2013 10:09:18 AM
NovaRx Corporation Completes Enrollment in Lucanix Pivitol Phase III Therapeutic Vaccine Trial for Post Frontline Maintenace Therapy in Non Small Cell Lung Cancer 6/20/2012 10:39:46 AM
NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer 11/4/2009 7:57:04 AM
NovaRx Corporation Appoints Industry Veteran as President and COO 12/4/2008 9:47:11 AM
NovaRx Corporation Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 8/21/2008 7:30:17 AM
NovaRx Corporation Selects Image Solutions, Inc. (ISI)'s eCTDXPress and ISIWriter 5/1/2008 8:42:33 AM
The Immune Response Corporation, Inc. (IMNR) Announces Receipt Of Milestone Payment From NovaRx Corporation 1/5/2007 11:50:51 AM
NovaRx Corporation Release: Lucanix Phase II Clinical Data Demonstrates Significantly Increased Survival In Lung Cancer Patients 6/5/2006 10:22:27 AM
NovaRx Corporation To Present Lucanix Phase II Clinical Data At American Society of Clinical Oncology 5/31/2006 10:19:59 AM
12
//-->